Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study

Rhea-AI Summary

Immunovia (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, has announced a webcast scheduled for March 24, 2025, at 3 pm CET to present additional results from their successful VERIFI clinical validation study. The study results, initially published on March 19, 2025, were positive for their next-generation pancreatic cancer test.

CEO Jeff Borcherding and VP Clinical and Medical Affairs Dr. Norma Alonzo Palma will lead the English-language presentation, which will include a Q&A session. The company focuses on developing blood-based testing to detect proteins and antibodies indicating high-risk pancreatic cancer cases.

Immunovia estimates that 1.8 million individuals in the USA, their largest target market, are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

LUND, Sweden, March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.

Jeff Borcherding, Immunovia CEO and Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs will present additional study results and share implications of the study. 

The webcast will be held in English and will offer attendees the opportunity to ask questions. Here is the link to join the webcast: 
https://access.creomediamanager.com/registration/5a1817e6-d829-4839-bbb7-67368c517927?ref=https%3A%2F%2Fcreo-live.creomediamanager.com%2F5a1817e6-d829-4839-bbb7-67368c517927

A recording of the presentation will be available on Immunovia's website following the webcast.

For further information, please contact:
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-webcast-to-share-more-data-from-the-successful-verifi-clinical-validation-study,c4122468

The following files are available for download:

https://mb.cision.com/Main/13121/4122468/3336499.pdf

Press release (PDF)

 

View original content:https://www.prnewswire.com/news-releases/immunovia-to-host-a-webcast-to-share-more-data-from-the-successful-verifi-clinical-validation-study-302407990.html

SOURCE Immunovia AB

FAQ

When is Immunovia's VERIFI study webcast and what will it cover?

Immunovia's webcast is scheduled for March 24, 2025, at 3 pm CET, presenting additional results from the VERIFI clinical validation study of their pancreatic cancer test.

What is the market potential for Immunovia's (IMMNOV) pancreatic cancer test in the USA?

Immunovia estimates 1.8 million high-risk individuals in the USA could benefit from annual pancreatic cancer surveillance testing.

What type of diagnostic test is Immunovia (IMMNOV) developing?

Immunovia is developing blood-based tests that detect proteins and antibodies indicating high-risk for pancreatic cancer.

When did Immunovia (IMMNOV) announce the VERIFI study results?

Immunovia published the positive VERIFI clinical validation results on March 19, 2025.

Who will present at Immunovia's March 2025 VERIFI study webcast?

CEO Jeff Borcherding and VP Clinical and Medical Affairs Dr. Norma Alonzo Palma will present at the webcast.